Michael Thomas Heffernan has an estimated net worth of $40 Million. This is based on reported shares across multiple companies, which include COLLEGIUM PHARMACEUTICAL, INC, Biohaven Pharmaceutical Holding Co Ltd., Trevi Therapeutics, Inc., SYNLOGIC, INC., Akebia Therapeutics, Inc., Biohaven Ltd., Ocata Therapeutics, Inc., CORNERSTONE THERAPEUTICS INC, KERYX BIOPHARMACEUTICALS INC, Avalo Therapeutics, Inc., and enGene Holdings Inc..

2022 was Michael Thomas Heffernan's most active year for acquiring shares with 26 total transactions. Michael Thomas Heffernan's most active month to acquire stocks was the month of May. 2022 was Michael Thomas Heffernan's most active year for disposing of shares, totalling 31 transactions. Michael Thomas Heffernan's most active month to dispose stocks was the month of November. 2020 saw Michael Thomas Heffernan paying a total of $1,578,402.99 for 445,815 shares, this is the most they've acquired in one year. In 2020 Michael Thomas Heffernan cashed out on 627,474 shares for a total of $7,678,811.26, their largest year based on trade value.